Mabwell News

Legal Opinion of Beijing Zhide (Shanghai) Law Firm on the 2024 Third Extraordinary General Meeting of Shareholders of Maiwei (Shanghai) Biotechnology Co., Ltd.

Sep 19 12:00 ET

Announcement of Resolutions of the 2024 Third Extraordinary General Meeting of Shareholders of Maiwei Biotech

Sep 19 12:00 ET

Notice of Maiwei Biotech on convening the 3rd Extraordinary General Meeting of Shareholders in 2024

Aug 30 12:00 ET

Maiwei Biotech\'s 2024 “Improve Quality, Increase Efficiency, and Reward” Action Plan

Aug 30 12:00 ET

Maiwei Biotech 2024 3rd Extraordinary General Meeting of Shareholders Meeting Information

Aug 30 12:00 ET

Meiwei Biotech voluntarily disclosed the announcement that the Phase III clinical study of 9MW2821 combined with PD-1 monoclonal antibody for first-line treatment of urothelial carcinoma has obtained approval from the CDE.

Aug 25 12:00 ET

Maivi Bioscience voluntarily discloses the announcement regarding the phase III clinical study of 9MW2821 for the treatment of cervical cancer approved by the CDE.

Aug 22 12:00 ET

Meiwei Biopharmaceutical voluntarily disclosed the announcement on the inclusion of 9MW2821 for the indication of urothelial carcinoma into breakthrough therapy drugs.

Aug 11 12:00 ET

The verification opinion on the change of part of the fundraising special account and the re-signing of the four-party regulatory agreement by Maiwei (Shanghai) biotechnology Co., Ltd., submitted by Haitong Securities Co., Ltd.

Aug 1 12:00 ET

Announcement from Maiwei Biology regarding its wholly-owned subsidiary's signing of a licensing agreement with Runjia Pharmaceutical.

Aug 1 12:00 ET

Announcement on the change of the special account for raising funds and the re-signing of the quadrilateral supervision agreement by Maiwei Biology.

Aug 1 12:00 ET

Announcement of resolutions from the second extraordinary shareholders' meeting of Maiwei Biotech in 2024.

Jun 12 12:00 ET

Legal Opinion from Beijing Zhede (Shanghai) Law Firm regarding the 2024 Second Extraordinary General Meeting of Shareholders of Maui (Shanghai) Biotechnology Co., Ltd.

Jun 12 12:00 ET

Notice of Maiwei Biotech on convening the 2nd Extraordinary General Meeting of Shareholders in 2024

May 23 12:00 ET

Announcement of Maiwei Biotech regarding the termination and re-provision of guarantees by the Company and its wholly-owned subsidiaries for wholly-owned subsidiaries

May 23 12:00 ET

Maiwei Biotech's announcement on the resignation of independent directors, nomination of independent directors, and adjustment of members of the 2nd Board of Directors Special Committee

May 23 12:00 ET

Maiwei Biotech voluntarily discloses an announcement on 9MW2821 to report clinical data and latest developments in the form of an oral report at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23 12:00 ET

Maiwei Biotech 2024 Second Extraordinary General Meeting of Shareholders Meeting Information

May 23 12:00 ET

Announcement of Maiwei Biotech on its wholly-owned subsidiary opening a special account to raise funds and signing a quadripartite supervisory agreement for special fund raising account storage

May 20 12:00 ET

Maiwei Biotech voluntarily discloses an announcement on the progress of clinical research on 9MW2821 for triple negative breast cancer indications (TNBC)

May 12 12:00 ET